Janssen receives MHRA authorization for Ponvory in RMS

11 August 2021
janssen_ponvory_large

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Marketing Authorization in Great Britain for Ponvory (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Marketed by US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen unit, Ponvory gained US regulatory approval in March this year and in Europe in May. Analysts have forecast peak potential sales of $200 to $400 million for ponesimod.

The MHRA authorization of ponesimod is based on data from the Phase III OPTIMUM trial, a multicenter, randomized, double-blind, parallel-group, active-controlled superiority study of 1,133 adult patients (aged 18-55 years) with RMS in 28 countries. The trial was designed to evaluate the efficacy and safety of once-daily oral ponesimod (20mg) versus once-daily teriflunomide (14mg), an approved and established first-line oral treatment, in adult patients with RMS markted by Sanof (Euronext: SAN) as Aubagio

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology